Zoetis Inc. ZTS
Healthcare · Drug Manufacturers - Specialty & Generic · United States · S&P 500
Based on the available data, Zoetis Inc. gets an algorithmic score of 55/100. It trades at 70.30 $, with a bearish technical trend (RSI 37.9) and 37.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (64.9%): generates strong profit on equity.
- High net margin (27.7%): pricing power / competitive advantage.
- Attractive free-cash-flow yield (7.9%).
- Low valuation (P/E 10.8).
- Low beta (0.62): defensive profile.
- Meaningful dividend (3.02%).
Weaknesses
- High leverage (debt/equity 294%): rate-sensitive.
Fundamentals
| P/E | 11.47 |
| Forward P/E | 10.76 |
| PEG | 6.66 |
| P/B | 8.97 |
| EV/EBITDA | 9.01 |
| P/S | 3.05 |
| ROE % | 64.91 |
| ROA % | 15.35 |
| Gross margin % | 71.74 |
| Operating margin % | 40.72 |
| Net margin % | 27.68 |
| Revenue growth % (y/y) | -0.20 |
| Earnings growth % (y/y) | 1.20 |
| Revenue CAGR % | 5.42 |
| Earnings CAGR % | 8.13 |
| Debt/Equity % | 294.00 |
| Current ratio | 3.08 |
| FCF yield % | 7.86 |
| Dividend yield % | 3.02 |
| Payout % | 33.61 |
Returns
| 1 month | -9.1 % |
| 3 months | -1.5 % |
| 6 months | -38.9 % |
| YTD | -43.3 % |
| 1 year | -50.1 % |
| 3 years | -58.5 % |
| 5 years | -63.0 % |
Risk
| 1-year volatility | 37.8 % |
| Beta | 0.62 |
| 5-year max drawdown | -70.0 % |
| Sharpe 1A | -1.74 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.